Toward a new Horizon in Huntington Disease
TRIAL ENROLLMENT HAS BEEN COMPLETED No new patients are being enrolled

What is the Horizon Trial?

The Horizon Trial is a Phase 3 clinical research trial to test whether dimebon (latrepirdine) safely improves cognition (thinking and awareness) in patients with Huntington disease.

The Horizon Trial is being conducted as a collaboration between the Huntington Study Group (HSG) and the European Huntington's Disease Network (EHDN) under the sponsorship of Medivation and Pfizer.

What is dimebon (latrepirdine)?

Dimebon (latrepirdine) has a unique mechanism of action, distinct from currently available treatments. In preclinical studies, dimebon has been shown to protect brain cells from damage and enhance brain cell survival, potentially by stabilizing and improving mitochondrial function.